For Research Use Only. Not for use in diagnostic procedures.

Chromosome: 6; NC_000006.11 (43737946..43754224). Location: 6p12

Purified
~88% as determined by HPLC analysis.

Supplied as a lyophilized powder. Reconstitute with sterile dH2O.

Prior to reconstitution store at +4 degree C.
After reconstitution store at -20 degree C.
Storage in frost-free freezers is not recommended. This product should be stored undiluted. Avoid repeated freezing and thawing as this may denature the protein. Should this product contain a precipitate we recommend microcentrifugation before use.

Small volumes of VEGFA protein vial(s) may occasionally become entrapped in the seal of the product vial during shipment and storage. If necessary, briefly centrifuge the vial on a tabletop centrifuge to dislodge any liquid in the container`s cap. Certain products may require to ship with dry ice and additional dry ice fee may apply.

Growth Factors, Cytokines; Growth Factors-VEGF

ELISA (EL/EIA)

Suitable for use in ELISA.

27,042 Da[Similar Products]

vascular endothelial growth factor A

vascular endothelial growth factor A; vascular permeability factor

Vascular endothelial growth factor A

VEGF; VEGF-A; VPF??[Similar Products]

VEGFA_HUMAN

This gene is a member of the PDGF/VEGF growth factor family and encodes a protein that is often found as a disulfide linked homodimer. This protein is a glycosylated mitogen that specifically acts on endothelial cells and has various effects, including mediating increased vascular permeability, inducing angiogenesis, vasculogenesis and endothelial cell growth, promoting cell migration, and inhibiting apoptosis. Elevated levels of this protein is linked to POEMS syndrome, also known as Crow-Fukase syndrome. Mutations in this gene have been associated with proliferative and nonproliferative diabetic retinopathy. Alternatively spliced transcript variants, encoding either freely secreted or cell-associated isoforms, have been characterized. There is also evidence for the use of non-AUG (CUG) translation initiation sites upstream of, and in-frame with the first AUG, leading to additional isoforms. [provided by RefSeq, Jul 2008]

VEGF iso14: Growth factor active in angiogenesis, vasculogenesis and endothelial cell growth. Induces endothelial cell proliferation, promotes cell migration, inhibits apoptosis and induces permeabilization of blood vessels. Binds to the FLT1/VEGFR1 and KDR/VEGFR2 receptors, heparan sulfate and heparin. NRP1/Neuropilin-1 binds isoforms VEGF-165 and VEGF-145. Isoform VEGF165B binds to KDR but does not activate downstream signaling pathways, does not activate angiogenesis and inhibits tumor growth. Defects in VEGFA are a cause of susceptibility to microvascular complications of diabetes type 1 (MVCD1). These are pathological conditions that develop in numerous tissues and organs as a consequence of diabetes mellitus. They include diabetic retinopathy, diabetic nephropathy leading to end-stage renal disease, and diabetic neuropathy. Diabetic retinopathy remains the major cause of new-onset blindness among diabetic *****s. It is characterized by vascular permeability and increased tissue ischemia and angiogenesis. Belongs to the PDGF/VEGF growth factor family. 13 isoforms of the human protein are produced by alternative promoter.

Protein type: Cytokine; Secreted; Secreted, signal peptide; Motility/polarity/chemotaxis

Chromosomal Location of Human Ortholog: 6p12

Cellular Component: proteinaceous extracellular matrix; extracellular space; cell surface; membrane; cytoplasm; extracellular region; secretory granule

Molecular Function: heparin binding; identical protein binding; protein binding; protein homodimerization activity; growth factor activity; extracellular matrix binding; vascular endothelial growth factor receptor 2 binding; protein heterodimerization activity; fibronectin binding; cytokine activity; platelet-derived growth factor receptor binding; vascular endothelial growth factor receptor 1 binding; vascular endothelial growth factor receptor binding; receptor agonist activity; chemoattractant activity

Biological Process: heart morphogenesis; positive regulation of positive chemotaxis; positive regulation of cell adhesion; macrophage differentiation; positive regulation of leukocyte migration; positive regulation of receptor internalization; cell maturation; basophil chemotaxis; positive regulation of MAP kinase activity; regulation of cell shape; positive chemotaxis; positive regulation of mesenchymal cell proliferation; mesoderm development; kidney development; platelet activation; positive regulation of neuroblast proliferation; nervous system development; monocyte differentiation; positive regulation of blood vessel endothelial cell migration; activation of CREB transcription factor; positive regulation of protein amino acid autophosphorylation; positive regulation of vascular permeability; patterning of blood vessels; regulation of transcription from RNA polymerase II promoter; eye photoreceptor cell development; positive regulation of peptidyl-tyrosine phosphorylation; positive regulation of angiogenesis; camera-type eye morphogenesis; branching morphogenesis of a tube; cell migration during sprouting angiogenesis; cardiac muscle fiber development; positive regulation of cell division; activation of protein kinase activity; positive regulation of axon extension involved in axon guidance; positive regulation of transcription from RNA polymerase II promoter; positive regulation of endothelial cell proliferation; regulation of cGMP metabolic process; surfactant homeostasis; positive regulation of epithelial cell proliferation; negative regulation of apoptosis; lactation; post-embryonic camera-type eye development; negative regulation of transcription from RNA polymerase II promoter; negative regulation of caspase activity; positive regulation of vascular endothelial growth factor receptor signaling pathway; induction of positive chemotaxis; platelet degranulation; positive regulation of focal adhesion formation; ovarian follicle development; epithelial cell differentiation; positive regulation of cell proliferation; angiogenesis; vasculogenesis; in utero embryonic development; lumen formation; positive regulation of cell motility; positive regulation of peptidyl-serine phosphorylation; positive regulation of protein complex assembly; response to hypoxia; artery morphogenesis; positive regulation of protein amino acid phosphorylation; blood coagulation; vascular endothelial growth factor receptor signaling pathway; lung development; positive regulation of cell migration; growth

Disease: Microvascular Complications Of Diabetes, Susceptibility To, 1

All of MyBioSource's Products are for scientific laboratory research purposes and are not for diagnostic, therapeutics, prophylactic or in vivo use. Through your purchase, you expressly represent and warrant to MyBioSource that you will properly test and use any Products purchased from MyBioSource in accordance with industry standards. MyBioSource and its authorized distributors reserve the right to refuse to process any order where we reasonably believe that the intended use will fall outside of our acceptable guidelines.

While every efforts were made to ensure the accuracy of the information provided in this datasheet, MyBioSource will not be liable for any omissions or errors contained herein. MyBioSource reserves the right to make changes to this datasheet at any time without prior notice.

It is the responsibility of the customer to report product performance issues to MyBioSource within 30 days of receipt of the product. Please visit our Terms & Conditions page for more information.